Chemistry: analytical and immunological testing – Involving production or treatment of antibody – Monoclonal antibody
Patent
1990-03-29
1992-12-29
Kepplinger, Esther L.
Chemistry: analytical and immunological testing
Involving production or treatment of antibody
Monoclonal antibody
436518, 436804, 435 71, 435 75, 435 792, 435 793, 424 858, 5303879, 53038885, 5303911, 5303913, 530403, G01N 33577, G01N 3353, C07K 1528
Patent
active
051751135
ABSTRACT:
Substantially pure modified .beta..sub.2 -microglobulin (m.beta..sub.2 m) of the formula I ##STR1## wherein R.sub.1 is 24-amino acid residue, with the sequence Ile-Gln-Arg-Thr-Pro-Lys-Ile-Gln-Val-Tyr-Ser-Arg-His-Pro-Ala-Glu-Asn-Gly-Ly s-Ser-Asn-Phe-Leu-Asn, R.sub.2 is a 30-amino acid residue with the sequence Tyr-Val-Ser-Gly-Phe-His-Pro-Ser-Asp-Ile-Glu-Val-Asp-Leu-Leu-Lys-Asn-Gly-Gl u-Arg-Ile-Gly-Lys-Val-Glu-His-Ser-Asp-Leu-Ser, R.sub.3 is a 20-amino acid residue with the sequence Trp-Ser-Phe-Tyr-Leu-Leu-Tyr-Tyr-Glu-Phe-Thr-Pro-Thr-Glu-Lys-Asp-Glu-Tyr-Al a, R.sub.4 is a 19-amino acid residue with the sequence Arg-Val-Asn-His-Val-Thr-Leu-Ser-Gln-Pro-Lys-Ile-Val-Lys-Trp-Asp-Arg-Asp-Me t, X is Phe, Phe-Ser, or Phe-Ser-Lys, and Y is Asp, Lys-Asp, or Ser-Lys-Asp is disclosed. The presence of the protein in body fluids is a diagnostic and/or prognostic marker for the development of a variety of disorders such as different types of cancer and diseases involving the immune system. Also disclosed are specific anti-m.beta..sub.2 m antibodies used for the detection and quantification of m.beta..sub.2 m.
REFERENCES:
patent: 4376110 (1983-03-01), David et al.
Hopp et al, "Prediction of protein antigenic determinants from amino acid sequences" Proc. Natl. Acad. Sci. USA, 78(6):3824-3828 (Jun. 1981).
Hopp et al, "A Computer Program for Predicting Protein Antigenic Determinants" Mol. Immunol. 20(4):483-489 (1983).
Taggart et al, "Stable Antibody-Producing Murine Hybridomas", Science 219:1228-30 (Mar. 11, 1983).
Wide "Chapter 13 Noncompetitive Versus Competitive Binding Assays" in Principles of Competitive Protein-Binding Assays, 2nd Ed. pp. 243-254 (1983).
ATCC (American Type Culture Collection) Catalogue of Cell Lines and Hybridomas Fifth Edition, pp. 212, 217 and 222 (1985).
The Calbiochem Biochemical and Immunochemical Catalog, pp. 204-205 (1985).
Cunningham, et al., Biochem. 12(24):4811-4821 (1973).
Suggs et al., Proc. Natl. Acad. Sci. USA 78(11):6613-6617 (1981).
Plesner et al., Scand. J. Immunol. 11:341-351 (1980).
Bhalla et al., Clinical Chemistry 31(8):1411 (1985).
Peterson et al., Proc. Nat. Acad. Sci. USA 71(1):35-39 (1974).
Terhorst et al., Cell (23):771-780 (1981).
Nissen, et al. Clinica Chimica Acta 141:41-50 (1984).
Plesner et al., Scand J. Immunol. 9:247-254 (1979).
Plesner, T. Allergy 35:627-637 (1980).
Plesner, et al., Scand. J. Clin. Lab. Invest. 35:729-735 (1975).
Christensen Mogens
Larsen Flemming S.
Nissen Mogens H.
Thim Lars
Zeuthen Jesper
Bidwell Carol E.
Kepplinger Esther L.
Novo Nordisk A S
LandOfFree
Modified .beta..sub.2 -microglobulin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified .beta..sub.2 -microglobulin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified .beta..sub.2 -microglobulin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1886751